New insight into the effects of heparinoids on complement inhibition by C1-inhibitorPoppelaars, F., Damman, J., de Vrij, E. L., Burgerhof, J. G. M., Saye, J., Daha, M. R., Leuvenink, H. G., Uknis, M. E. & Seelen, M. A. J., Jun-2016, In : Clinical and Experimental Immunology. 184, 3, p. 378-388 11 p.
Research output: Contribution to journal › Article › Academic › peer-review
Complement activation is of major importance in numerous pathological conditions. Therefore, targeted complement inhibition is a promising therapeutic strategy. C1-esterase inhibitor (C1-INH) controls activation of the classical pathway (CP) and the lectin pathway (LP). However, conflicting data exist on inhibition of the alternative pathway (AP) by C1-INH. The inhibitory capacity of C1-INH for the CP is potentiated by heparin and other glycosaminoglycans, but no data exist for the LP and AP. The current study investigates the effects of C1-INH in the presence or absence of different clinically used heparinoids on the CP, LP and AP. Furthermore, the combined effects of heparinoids and C1-INH on coagulation were investigated. C1-INH, heparinoids or combinations were analysed in a dosedependent fashion in the presence of pooled serum. Functional complement activities were measured simultaneously using the Wielisa (R)-kit. The activated partial thrombin time was determined using an automated coagulation analyser. The results showed that all three complement pathways were inhibited significantly by C1-INH or heparinoids. Next to their individual effects on complement activation, heparinoids also enhanced the inhibitory capacity of C1-INH significantly on the CP and LP. For the AP, significant potentiation of C1-INH by heparinoids was found; however, this was restricted to certain concentration ranges. At low concentrations the effect on blood coagulation by combining heparinoids with C1-INH was minimal. In conclusion, our study shows significant potentiating effects of heparinoids on the inhibition of all complement pathways by C1-INH. Therefore, their combined use is a promising and a potentially cost-effective treatment option for complement-mediated diseases.
|Number of pages||11|
|Journal||Clinical and Experimental Immunology|
|Publication status||Published - Jun-2016|
- complement, complement 1-inhibitor, glycosaminoglycans, heparinoids, inhibition, C1 INHIBITOR, HEREDITARY ANGIOEDEMA, TARGETING COMPLEMENT, PREDOMINANT ROLE, ACTIVATION, TRANSPLANTATION, PATHWAY, GENERATION, PLASMA, LECTIN